The majority of participants were unaware of the existence of new medications for FH patients besides statins, such as PCSK9 inhibitors, Lomitapide (MTP) inhibitors, and Mipomersen (an antisense oligonucleotide inhibitor) (Table 2). This evidence concerns the gene PCSK9 and familial hyperaldosteronism.